Ronco C, Bellomo R
Department of Nephrology, Dialysis and Transplantation, St Bortolo Hospital, Vicenza, Italy.
Int J Artif Organs. 2002 Aug;25(8):733-47. doi: 10.1177/039139880202500801.
Renal replacement therapy (RRT) has evolved from the concept that we need to treat the dysfunction of a single organ (the kidney). As intensive care units have become more and more complex, it has become clear that the majority of patients with acute renal failure often have dysfunction of several other organs. In order to facilitate single organ support in this setting, continuous renal replacement therapy (CRRT) techniques have been developed. However, CRRT has opened the door to the concept that targeting renal support as the only goal of extracorporeal blood purification may be a simplistic view of our therapeutic aims. In this article we argue that it is now time to move from the simple goal of achieving adequate renal support. The proper goal of extracorporeal blood purification in ICU should be multi-organ support therapy (MOST). We explain why MOST represents the most logical future conceptual and practical evolution of CRRT and illustrates the biological rationale, supplying animal and clinical evidence that confirms the need to move rapidly in this direction theoretically, practically and technologically.
肾脏替代疗法(RRT)已从我们需要治疗单一器官(肾脏)功能障碍的概念发展而来。随着重症监护病房变得越来越复杂,很明显,大多数急性肾衰竭患者通常还伴有其他几个器官的功能障碍。为了便于在这种情况下进行单一器官支持,连续肾脏替代疗法(CRRT)技术应运而生。然而,CRRT开启了这样一种观念,即把肾脏支持作为体外血液净化的唯一目标可能是对我们治疗目的的一种过于简单化的看法。在本文中,我们认为现在是时候从单纯实现充分肾脏支持的目标转变了。重症监护病房体外血液净化的恰当目标应该是多器官支持疗法(MOST)。我们解释了为什么MOST代表了CRRT最合乎逻辑的未来概念和实践演变,并阐述了生物学原理,提供了动物和临床证据,从理论、实践和技术上证实了有必要朝着这个方向迅速迈进。